Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL3727181

Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1-c1ccc(CNS(=O)(=O)N(C)C)cc1.N

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 11/20 0.52
CDK1 P06493 10/20 0.52
CCNT1 O60563 8/20 0.52
CCNB1 P14635 8/20 0.52
CDK9 P50750 8/20 0.52
CCNA2 P20248 6/20 0.52
CDK7 P50613 5/20 0.52
CCNH P51946 5/20 0.52
CCNA1 P78396 4/20 0.52
JAK3 P52333 9/20 0.47
CDK5 Q00535 5/20 0.47
EGFR P00533 3/20 0.47
NTRK1 P04629 3/20 0.47
SYK P43405 3/20 0.47
FLT3 P36888 2/20 0.47
BTK Q06187 2/20 0.47
AURKA O14965 2/20 0.47
DCLK1 O15075 2/20 0.47
PDPK1 O15530 2/20 0.47
JAK2 O60674 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL14053387 0.88 CDK2 (0.53) CDK2CDK1CCNT1CCNB1CDK9
SCHEMBL2471890 0.87 JAK3 (0.63) CDK2CDK1CCNT1CCNB1CDK9
Ammonia Solution, Strong SCHEMBL14053403 0.85 CDK1 (0.50) CDK2CDK1CCNT1CCNB1CDK9
SCHEMBL17685307 0.84 JAK3 (0.59) CDK2CDK1CCNT1CCNB1CDK9
SCHEMBL2475718 0.81 NTRK1 (0.60) CDK2CDK1CCNT1CCNB1CDK9
SCHEMBL17685311 0.80 CSF1R (0.56) CDK2CDK1CCNT1CCNB1CDK9
SCHEMBL17685281 0.78 JAK3 (0.56) CDK2CDK1CCNA2JAK3CDK5
SCHEMBL2470647 0.77 CDK2 (0.53) CDK2CDK1CCNT1CCNB1CDK9
SCHEMBL4971164 0.76 JAK3 (0.65) CDK2CDK1CCNT1CCNB1CDK9
SCHEMBL2473715 0.75 JAK3 (0.64) CDK2CDK1CCNT1CCNB1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420659-B2 Compositions and methods for inhibition of the JAK pathway RIGEL PHARMACEUTICALS, INC. (US) 2013-04-16 US disclosed
US-20120301486-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY Riger Pharmaceuticals, Inc. 2012-11-29 US disclosed
US-8268851-B2 Compositions and methods for inhibition of the JAK pathway RIGEL PHARMACEUTICALS, INC. (US) 2012-09-18 US disclosed
US-20100158921-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS, INC. (US) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158921-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY JAK3, JAK2, JAK1 CDK2 236/4885CDK1 155/4885CCNT1 1524/4885
US-20120301486-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY JAK3, JAK2, JAK1 CDK2 236/4885CDK1 155/4885CCNT1 1524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.